Pancreas Powder, Porcine

Summary

Pancreas Powder, Porcine (CHEMBL5315084) is an approved unknown targeting NPY1R, NPY2R, and NPY4R; indicated across 1 condition including exocrine pancreatic insufficiency.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Unknown
• Targets: 4 (NPY1R, NPY2R, NPY4R…)
• Indications: 1 condition

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL5315084
Name	Pancreas Powder, Porcine
Type	Unknown
Max phase	4

Also known as: Enzepi, Pancreas powder, porcine, PANCREAS POWDER, PORCINE

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
NPY1R	Y1 receptor	Full agonist	7.8	0.5%	P25929
NPY2R	Y2 receptor	Full agonist	8.7	0%	P49146
NPY4R	Y4 receptor	Full agonist	6.9	40%	P50391
NPY5R	Y5 receptor	Full agonist	7.3	0%	Q15761

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 4 target gene(s): NPY1R, NPY2R, NPY4R, NPY5R.

Top Reactome pathways

2 total, by targets touching each:

Pathway	Targets	Genes
Peptide ligand-binding receptors	4	NPY1R, NPY2R, NPY4R, NPY5R
G alpha (i) signalling events	4	NPY1R, NPY2R, NPY4R, NPY5R

Dominant GO biological processes

GO term	Targets
signal transduction	4
G protein-coupled receptor signaling pathway	4
neuropeptide signaling pathway	4
outflow tract morphogenesis	3
cell communication	3
signaling	3
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway	2
locomotory behavior	2
cardiac left ventricle morphogenesis	2
synaptic signaling via neuropeptide	2
glucose metabolic process	1
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	1
feeding behavior	1
regulation of blood pressure	1
sensory perception of pain	1

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
exocrine pancreatic insufficiency	4	MONDO:0001684	MONDO:0001684

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

188 molecules share ≥1 primary target. Top 60 by shared-target count:

Molecule	Source	Status	Shared targets
PANCREATIC POLYPEPTIDE	ChEMBL	Phase 2	NPY1R, NPY4R, NPY5R
CANDESARTAN CILEXETIL	ChEMBL + PubChem	Phase 4 (approved)	NPY1R, NPY2R
CARVEDILOL	ChEMBL + PubChem	Phase 4 (approved)	NPY1R, NPY2R
CRIZOTINIB	ChEMBL + PubChem	Phase 4 (approved)	NPY1R, NPY2R
RIFAMPIN	ChEMBL + PubChem	Phase 4 (approved)	NPY1R, NPY2R
TAMOXIFEN	ChEMBL + PubChem	Phase 4 (approved)	NPY1R, NPY2R
TEGASEROD	ChEMBL + PubChem	Phase 4 (approved)	NPY1R, NPY2R
ECONAZOLE NITRATE	ChEMBL	Phase 4 (approved)	NPY1R, NPY2R
METOPROLOL	ChEMBL	Phase 4 (approved)	NPY1R, NPY2R
Acetylcholine	PubChem	Approved	NPY1R, NPY2R
Aclidinium Bromide	PubChem	Approved	NPY1R, NPY2R
Acyclovir	PubChem	Approved	NPY1R, NPY2R
Alendronic Acid	PubChem	Approved	NPY1R, NPY2R
Allopurinol	PubChem	Approved	NPY1R, NPY2R
Alogliptin	PubChem	Approved	NPY1R, NPY2R
Alprazolam	PubChem	Approved	NPY1R, NPY2R
Amiloride	PubChem	Approved	NPY1R, NPY2R
Amitriptyline	PubChem	Approved	NPY1R, NPY2R
Amlodipine	PubChem	Approved	NPY1R, NPY2R
Amoxapine	PubChem	Approved	NPY1R, NPY2R
Beclomethasone	PubChem	Approved	NPY1R, NPY2R
Beclomethasone Dipropionate	PubChem	Approved	NPY1R, NPY2R
Bosentan	PubChem	Approved	NPY1R, NPY2R
Clozapine	PubChem	Approved	NPY1R, NPY2R
Desloratadine	PubChem	Approved	NPY1R, NPY2R
Dihydroergotamine	PubChem	Approved	NPY1R, NPY2R
Ethambutol	PubChem	Approved	NPY1R, NPY2R
Fidaxomicin	PubChem	Approved	NPY1R, NPY2R
Methotrexate	PubChem	Approved	NPY1R, NPY2R
Naproxen	PubChem	Approved	NPY1R, NPY2R
Olanzapine	PubChem	Approved	NPY1R, NPY2R
Olmesartan Medoxomil	PubChem	Approved	NPY1R, NPY2R
Phenytoin	PubChem	Approved	NPY1R, NPY2R
Pimozide	PubChem	Approved	NPY1R, NPY2R
Propoxyphene	PubChem	Approved	NPY1R, NPY2R
Pyrazinamide	PubChem	Approved	NPY1R, NPY2R
Sildenafil	PubChem	Approved	NPY1R, NPY2R
Stavudine	PubChem	Approved	NPY1R, NPY2R
Sulindac	PubChem	Approved	NPY1R, NPY2R
theophylline	PubChem	Approved	NPY1R, NPY2R
Tiotropium Bromide Monohydrate	PubChem	Approved	NPY1R, NPY2R
Valacyclovir	PubChem	Approved	NPY1R, NPY2R
AMSACRINE	ChEMBL	Phase 4 (approved)	NPY1R
CHLORHEXIDINE	ChEMBL	Phase 4 (approved)	NPY1R
ECONAZOLE	ChEMBL	Phase 4 (approved)	NPY2R
FENTICONAZOLE	ChEMBL	Phase 4 (approved)	NPY1R
HEXACHLOROPHENE	ChEMBL	Phase 4 (approved)	NPY1R
LANSOPRAZOLE	ChEMBL	Phase 4 (approved)	NPY1R
LASOFOXIFENE	ChEMBL	Phase 4 (approved)	NPY1R
MITOXANTRONE	ChEMBL	Phase 4 (approved)	NPY1R
NEBIVOLOL	ChEMBL	Phase 4 (approved)	NPY1R
NITAZOXANIDE	ChEMBL	Phase 4 (approved)	NPY1R
PYRVINIUM	ChEMBL	Phase 4 (approved)	NPY1R
RABEPRAZOLE	ChEMBL	Phase 4 (approved)	NPY1R
RIFAXIMIN	ChEMBL	Phase 4 (approved)	NPY1R
SUNITINIB	ChEMBL	Phase 4 (approved)	NPY1R
TERFENADINE	ChEMBL	Phase 4 (approved)	NPY1R
THIORIDAZINE	ChEMBL	Phase 4 (approved)	NPY1R
TRIFLUOPERAZINE	ChEMBL	Phase 4 (approved)	NPY1R
BENSERAZIDE	ChEMBL	Phase 3	NPY1R